Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

van Vollenhoven, RF; Hahn, BH; Tsokos, GC; Wagner, CL; Lipsky, P; Touma, Z; Werth, VP; Gordon, RM; Zhou, B; Hsu, B; Chewier, M; Triebel, M; Jordan, JL; Rose, S

van Vollenhoven, RF (reprint author), Amsterdam Rheumatol & Immunol Ctr, NL-1007 MB Amsterdam, Netherlands.

LANCET, 2018; 392 (10155): 1330

Abstract

Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriat......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索